Publication Date:
2020-07-07
Description:
While improving representation of racial and ethnic groups in United States (US) clinical trials has been a focus of federal initiatives for nearly three decades; the status of racial/ethnic minority enrollment on cancer trials is largely unknown. We utilized a broad collection of phase 3 cancer trials derived from ClinicalTrials.gov to evaluate racial/ethnic enrollment among US cancer trials. The difference in incidence by race/ethnicity (D-IRE) was the median absolute difference between trial and corresponding Surveillance, Epidemiology, and End Results (SEER) data. All statistical tests were two-sided. Using a cohort of 168 eligible trials, median D-IRE was +6.8% for Whites (IQR +1.8%, +10.1%, p
Electronic ISSN:
2515-5091
Topics:
Chemistry and Pharmacology
,
Medicine
Permalink